EcoDrugPlus

Porcupine O-Acyltransferase

Ensembl ID : ENSTRUG00000000228
Gene Symbol: PORCN
3 Cross references
193 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSTRUG00000026674
Gene Symbol: PORCN
3 Cross references
196 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSTRUG00000014048
Gene Symbol: KCNMA1
3 Cross references
241 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSTRUG00000012523
Gene Symbol: KCNJ2
3 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSTRUG00000007530
Gene Symbol: KCNJ3
3 Cross references
224 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSTRUG00000007361
Gene Symbol: KCNJ5
4 Cross references
202 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSTRUG00000013276
Gene Symbol: KCNK2
3 Cross references
213 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSTRUG00000008997
Gene Symbol: KCNK2
1 Cross references
209 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSTRUG00000017711
Gene Symbol: KCNK3
3 Cross references
200 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSTRUG00000009408
Gene Symbol: KCNK9
3 Cross references
218 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSTRUG00000012622
Gene Symbol: KCND3
3 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3-Like

Ensembl ID : ENSTRUG00000006840
Gene Symbol: LOC101073956
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).